Processa Pharmaceuticals (PCSA) Q1 2026 earnings summary

Executive summary

• Focused on developing Next Generation Cancer (NGC) therapies, with one drug in Phase 2 and another in preclinical development.

• Pipeline includes two oncology drugs (NGC-Cap, NGC-Iri) and two non-oncology drugs, with out-licensing options being explored for the latter.

• No product revenue generated; all efforts are on R&D and clinical trials.

Financial highlights

• Net loss of $3.4 million for Q1 2026, compared to $2.8 million in Q1 2025.

• Research and development expenses rose to $1.8 million (up $221,000 year-over-year), mainly due to increased consulting for Phase 2 trials.

• General and administrative expenses increased to $1.5 million (up $264,000 year-over-year), driven by higher professional fees, insurance, and salaries.

• Cash and cash equivalents at March 31, 2026 were $1.7 million, down from $5.5 million at year-end 2025.

• Accumulated deficit reached $104.2 million as of March 31, 2026.

Outlook and guidance

• Additional capital will be needed in Q2 2026 to fund operations; current cash and recent raises are insufficient for one year of operations.

• Plans to raise funds through equity, debt, or strategic transactions; failure to secure funding may delay or suspend clinical programs.

• No expectation of positive cash flow from operations in the foreseeable future.